CAS No. 113942-30-6

Molecular Formula: C6H5N5O3
Molecular Weight: 195.137

Molecular Weight: 195.14
Molecular Formula: C6H5N5O3
Canonical SMILES: CN1C(=O)N2C=NC(=C2N=N1)C(=O)O
InChI: InChI=1S/C6H5N5O3/c1-10-6(14)11-2-7-3(5(12)13)4(11)8-9-10/h2H,1H3,(H,12,13)
InChIKey: VVTMIOYTNALQAW-UHFFFAOYSA-N
Boiling Point: No Data Available
Melting Point: >153°C (dec.)
Purity: 98%
Solubility: DMSO, Methanol
Application: as an antitumor agent.
Storage: -20°C Freezer
Synonyms: 3,4-Dihydro-3-methyl-4-oxo-imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylic Acid; 3-Methyl-4-oxo-8-imidazolo[5,1-d][1,2,3,5]tetrazinecarboxylic Acid; Temozolomide-8-carboxylic Acid; TMZA
Description
Temozolomide acid is an active metabolite of temozolomide(T017775) with anticancer activity in vitro. Temozolomide is an alkylating agent used as a treatment of some brain cancer, a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme.In Apr 2016, Stanford University and Merck suspended enrolment in a phase II trial for Acute myeloid leukaemia (Combination therapy, Newly diagnosed, Second-line therapy or greater) in USA. In 14 Jul 2016, Medivation planed a phase II trial for Endometrial cancer in USA (NCT02836028) After two days, M.D. Anderson Cancer Center completed a phase II trial in Malignant melanoma (Late-stage disease, Neoadjuvant therapy, Monotherapy, Combination therapy) in USA .


More details are to be found on supplier website